Cat. No.: HY-14654

Aspirin

(Synonyms: Acetylsalicylic acid; ASA)

38 Cited Publications

Avis client

Based on 38 publication(s) in Google Scholar

Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC₅₀ values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.67%
CAS No.: 50-78-2
Formule: C₉H₈O₄
Masse moléculaire:180.16

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Aspirin Chemical Structure

CAS No.: 50-78-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Induced Disease Models
- Essai clinique
Chemical Information
Publications (38)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]

COX-1

27.75 μM (IC₅₀)

COX-2

1.17 mM (IC₅₀)

Voir tous les produits spécifiques à Isoform NF-κB :

Voir tous les produits spécifiques à Isoform p38 MAPK :

Voir tous les produits spécifiques à Isoform COX :

Voir tous les produits spécifiques à Isoform Caspase :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>5000000 nM Compound: ASA	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 22916316]
A549	IC₅₀	>50 μM Compound: Aspirin	Cytotoxicity against human A549 cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human A549 cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
Bel-7402	IC₅₀	>100 μM Compound: Aspirin	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
Bel7402/5-FU	IC₅₀	>100 μM Compound: Aspirin	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
BGC-823	IC₅₀	>50 μM Compound: Aspirin	Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
BGC-823	IC₅₀	>50 μM Compound: Aspirin	Cytotoxicity against human BGC-823 cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
BXPC-3	IC₅₀	>5000000 nM Compound: ASA	Cytotoxicity against human BxPC3 cells expressing COX1 and COX2 after 24 hrs by MTT assay Cytotoxicity against human BxPC3 cells expressing COX1 and COX2 after 24 hrs by MTT assay	[PMID: 22916316]
Caco-2	IC₅₀	>50 μM Compound: Aspirin	Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
DLD-1	IC₅₀	>100 μM Compound: 1; ASA	Antiproliferative activity against human DLD1 cells after 72 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 72 hrs by MTT assay	[PMID: 30429977]
DU-145	IC₅₀	>100 μM Compound: 1; ASA	Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
Erythrocyte	IC₅₀	166 mM Compound: Aspirin	Antiinflammatory activity in human erythrocytes assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometry Antiinflammatory activity in human erythrocytes assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometry	[PMID: 25638040]
Erythrocyte	IC₅₀	166 μM/mL Compound: Aspirin	Antiinflammatory activity in human erythrocytes assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometry Antiinflammatory activity in human erythrocytes assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometry	[PMID: 25638040]
HaCaT	IC₅₀	30.4 μM Compound: Aspirin	Inhibition of ultraviolet B-irradiation upregulated of prostaglandin E2 production in human HaCaT cells measured after 2 hrs by ELISA Inhibition of ultraviolet B-irradiation upregulated of prostaglandin E2 production in human HaCaT cells measured after 2 hrs by ELISA	[PMID: 34463498]
HaCaT	IC₅₀	21.27 μM Compound: ASA	Antiinflammatory activity against human HaCaT cells assessed as inhibition of UVB irradiation-induced PGE2 production measured after 2 hrs by ELISA Antiinflammatory activity against human HaCaT cells assessed as inhibition of UVB irradiation-induced PGE2 production measured after 2 hrs by ELISA	[PMID: 35172097]
HCT-116	IC₅₀	>60 μM Compound: 3	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
HCT-116	IC₅₀	8 mM Compound: 41	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured upto 72 hrs by CCK-8 method Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured upto 72 hrs by CCK-8 method	[PMID: 38142509]
HCT-15	IC₅₀	>5000000 nM Compound: ASA	Cytotoxicity against COX deficient human HCT15 cells after 24 hrs by MTT assay Cytotoxicity against COX deficient human HCT15 cells after 24 hrs by MTT assay	[PMID: 22916316]
HCT-15	IC₅₀	>5000000 nM Compound: Aspirin	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 26323873]
HCT-8	IC₅₀	>100 μM Compound: 2; ASA	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 30037494]
HCT-8	IC₅₀	15.6 μM Compound: 2; ASA	Antiproliferative activity against human HCT8 cells after 72 hrs in presence of cinnamaldehyde by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs in presence of cinnamaldehyde by MTT assay	[PMID: 30037494]
HCT-8	IC₅₀	>100 μM Compound: 1; ASA	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 30429977]
HEK293	IC₅₀	10.2 mM Compound: 4	Cytotoxicity against HEK293 cells harboring pendrin P123S mutant after 72 hrs by MTT assay Cytotoxicity against HEK293 cells harboring pendrin P123S mutant after 72 hrs by MTT assay	[PMID: 28341401]
HeLa	IC₅₀	>50 μM Compound: Aspirin	Cytotoxicity against human HeLa cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human HeLa cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
HepG2	IC₅₀	3841 μM Compound: Aspirin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23153797]
HT-29	EC₅₀	>1000 μM Compound: ASA	Apoptosis induction in human HT29 cells after 24 hrs Apoptosis induction in human HT29 cells after 24 hrs	[PMID: 17441704]
HT-29	IC₅₀	>5000000 nM Compound: ASA	Cytotoxicity against human HT-29 cells expressing COX1 and COX2 after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells expressing COX1 and COX2 after 24 hrs by MTT assay	[PMID: 22916316]
HT-29	IC₅₀	>60 μM Compound: 3	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
HT-29	IC₅₀	>5000000 nM Compound: Aspirin	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 26323873]
HT-29	IC₅₀	>50 μM Compound: ASA	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	>50 μM Compound: ASA	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	>50 μM Compound: ASA	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	>100 μM Compound: 1; ASA	Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
HUVEC	IC₅₀	5 mM Compound: Aspirin	Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM1 expression measured after 6 hrs by FACS flow cytometry Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM1 expression measured after 6 hrs by FACS flow cytometry	10.1039/C0MD00262C
Jurkat	IC₅₀	>5000000 nM Compound: ASA	Cytotoxicity against human Jurkat cells expressing COX1 and COX2 after 24 hrs by MTT assay Cytotoxicity against human Jurkat cells expressing COX1 and COX2 after 24 hrs by MTT assay	[PMID: 22916316]
L02	IC₅₀	>100 μM Compound: Aspirin	Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
LNCaP	IC₅₀	>5000000 nM Compound: ASA	Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay	[PMID: 22916316]
MCF7	IC₅₀	>5000000 nM Compound: ASA	Cytotoxicity against human MCF7 cells expressing ER after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing ER after 24 hrs by MTT assay	[PMID: 22916316]
MCF7	IC₅₀	>50 μM Compound: Aspirin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
MCF7	IC₅₀	>100 μM Compound: 1; ASA	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
MCF7	IC₅₀	>50 μM Compound: Aspirin	Cytotoxicity against human MCF7 cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human MCF7 cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
MDA-MB-231	IC₅₀	>5000000 nM Compound: ASA	Cytotoxicity against ER deficient human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against ER deficient human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 22916316]
MDA-MB-231	IC₅₀	1510 μM Compound: Aspirin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23153797]
MDA-MB-231	IC₅₀	>50 μM Compound: ASA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	>50 μM Compound: ASA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	>50 μM Compound: ASA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
Mesenchymal stem cells	EC₅₀	>300 μM Compound: ASA	Induction of adiponectin secretion in human differentiated BMMSC cells measured at 5 day in the presence of IDX induction medium by ELISA Induction of adiponectin secretion in human differentiated BMMSC cells measured at 5 day in the presence of IDX induction medium by ELISA	[PMID: 35172097]
MIA PaCa-2	IC₅₀	>5000000 nM Compound: ASA	Cytotoxicity against COX deficient human MIAPaCa2 cells after 24 hrs by MTT assay Cytotoxicity against COX deficient human MIAPaCa2 cells after 24 hrs by MTT assay	[PMID: 22916316]
Microglia	IC₅₀	3.12 μM Compound: aspirin	Antineuroinflammatory activity in LPS-stimulated rat microglia cells assessed as inhibition of PMA-stimulated TXB2 release preincubated for 15 mins measured 70 mins after PMA challenge Antineuroinflammatory activity in LPS-stimulated rat microglia cells assessed as inhibition of PMA-stimulated TXB2 release preincubated for 15 mins measured 70 mins after PMA challenge	[PMID: 22153874]
Microglia	IC₅₀	3.2 nM Compound: Aspirin	Antineuroinflammatory activity in rat brain neonatal microglia Antineuroinflammatory activity in rat brain neonatal microglia	[PMID: 24279991]
Neutrophil	IC₅₀	>40 μM Compound: aspirin	Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release	[PMID: 17197180]
Neutrophil	IC₅₀	>40 μM Compound: aspirin	Antiinflammatory activity in neutrophils assessed as inhibition of oxygen radical generation Antiinflammatory activity in neutrophils assessed as inhibition of oxygen radical generation	[PMID: 17197180]
Neutrophil	IC₅₀	279.44 μg/mL Compound: Aspirin	Antiinflammatory activity in human neutrophils assessed inhibition of superoxide anions production Antiinflammatory activity in human neutrophils assessed inhibition of superoxide anions production	[PMID: 19006373]
Neutrophil	IC₅₀	518.5 μM Compound: Aspirin	Antiinflammatory activity in human neutrophils assessed as inhibition of respiratory burst Antiinflammatory activity in human neutrophils assessed as inhibition of respiratory burst	[PMID: 20576329]
PANC-1	IC₅₀	7.45 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human PANC1 cells after 48 hrs by alamar blue assay Cytotoxicity against human PANC1 cells after 48 hrs by alamar blue assay	[PMID: 22494617]
PANC-1	IC₅₀	9.75 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human PANC1 cells after 24 hrs by alamar blue assay Cytotoxicity against human PANC1 cells after 24 hrs by alamar blue assay	[PMID: 22494617]
PANC-1	IC₅₀	>50 μM Compound: ASA	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	>50 μM Compound: ASA	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	>50 μM Compound: ASA	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
PC-3	IC₅₀	7.71 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human PC3 cells after 24 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 24 hrs by alamar blue assay	[PMID: 22494617]
PC-3	IC₅₀	7.82 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human PC3 cells after 48 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 48 hrs by alamar blue assay	[PMID: 22494617]
PC-3	IC₅₀	>50 μM Compound: Aspirin	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
Platelet	IC₅₀	27 μM Compound: Aspirin	Antiplatelet activity against washed rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge Antiplatelet activity against washed rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge	[PMID: 11374966]
Platelet	IC₅₀	18 mg/kg Compound: Aspirin	Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	25 μM Compound: Aspirin	Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	31 μM Compound: Aspirin	Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	32.7 μM Compound: aspirin	Antiplatelet activity against citreated rabbit platelet assessed as arachidonic acid-induced platelet aggregation Antiplatelet activity against citreated rabbit platelet assessed as arachidonic acid-induced platelet aggregation	[PMID: 15730246]
Platelet	IC₅₀	>100 μM Compound: aspirin	Anticoagulant activity assessed as inhibition of thrombin induced rabbit platelet aggregation Anticoagulant activity assessed as inhibition of thrombin induced rabbit platelet aggregation	[PMID: 17197180]
Platelet	IC₅₀	151.6 μM Compound: aspirin	Anticoagulant activity assessed as inhibition of arachidonic acid induced rabbit platelet aggregation Anticoagulant activity assessed as inhibition of arachidonic acid induced rabbit platelet aggregation	[PMID: 17197180]
Platelet	IC₅₀	>100 μM Compound: Aspirin	Inhibition of thrombin-induced human platelet aggregation by light transmission aggregometer Inhibition of thrombin-induced human platelet aggregation by light transmission aggregometer	[PMID: 18547115]
Platelet	IC₅₀	153.2 μM Compound: Aspirin	Inhibition of collagen-induced human platelet aggregation by light transmission aggregometer Inhibition of collagen-induced human platelet aggregation by light transmission aggregometer	[PMID: 18547115]
Platelet	IC₅₀	340 μM Compound: ASA	Inhibition of U46619-induced platelet aggregation in rat blood Inhibition of U46619-induced platelet aggregation in rat blood	[PMID: 18556200]
Platelet	IC₅₀	420 μM Compound: ASA	Inhibition of collagen-induced platelet aggregation in rat blood Inhibition of collagen-induced platelet aggregation in rat blood	[PMID: 18556200]
Platelet	IC₅₀	53 μM Compound: ASA	Inhibition of epinephrine-induced platelet aggregation in rat blood Inhibition of epinephrine-induced platelet aggregation in rat blood	[PMID: 18556200]
Platelet	IC₅₀	66 μM Compound: ASA	Inhibition of NaAA-induced platelet aggregation in rat blood Inhibition of NaAA-induced platelet aggregation in rat blood	[PMID: 18556200]
Platelet	IC₅₀	>1000 μM Compound: ASA	Inhibition of ADP-induced platelet aggregation in rat blood Inhibition of ADP-induced platelet aggregation in rat blood	[PMID: 18556200]
Platelet	IC₅₀	25.5 μM Compound: 4	Inhibition of arachidonic acid-induced platelet aggregation in whole blood Inhibition of arachidonic acid-induced platelet aggregation in whole blood	[PMID: 19049433]
Platelet	IC₅₀	0.35 μM Compound: ASP	Antiplatelet activity in human platelets assessed as inhibition of arachidonic acid-induced platelet aggregation Antiplatelet activity in human platelets assessed as inhibition of arachidonic acid-induced platelet aggregation	[PMID: 19216076]
Platelet	IC₅₀	0.35 μM/L Compound: ASP	Antiplatelet activity in human platelets assessed as inhibition of arachidonic acid-induced platelet aggregation Antiplatelet activity in human platelets assessed as inhibition of arachidonic acid-induced platelet aggregation	[PMID: 19216076]
Platelet	IC₅₀	9.34 μM Compound: ASP	Antiplatelet activity in human platelets assessed as inhibition of ADP-induced platelet aggregation Antiplatelet activity in human platelets assessed as inhibition of ADP-induced platelet aggregation	[PMID: 19216076]
Platelet	IC₅₀	9.34 μM/L Compound: ASP	Antiplatelet activity in human platelets assessed as inhibition of ADP-induced platelet aggregation Antiplatelet activity in human platelets assessed as inhibition of ADP-induced platelet aggregation	[PMID: 19216076]
Platelet	IC₅₀	11.7 μg/mL Compound: ASA	Antiplatelet activity in human citreated platelet rich plasma assessed as inhibition of adrenaline-induced platelet aggregation preincubated before adrenaline challenge Antiplatelet activity in human citreated platelet rich plasma assessed as inhibition of adrenaline-induced platelet aggregation preincubated before adrenaline challenge	[PMID: 19380229]
Platelet	IC₅₀	21.5 μg/mL Compound: ASA	Antiplatelet activity in human citreated platelet rich plasma assessed as inhibition of adenosine diphosphate-induced platelet aggregation preincubated before adenosine diphosphate challenge Antiplatelet activity in human citreated platelet rich plasma assessed as inhibition of adenosine diphosphate-induced platelet aggregation preincubated before adenosine diphosphate challenge	[PMID: 19380229]
Platelet	IC₅₀	32.5 μg/mL Compound: ASA	Antiplatelet activity in human citreated platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated before arachidonic acid challenge Antiplatelet activity in human citreated platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated before arachidonic acid challenge	[PMID: 19380229]
Platelet	IC₅₀	20.6 μM Compound: aspirin	Antiplatelets aggregatory activity in human platelets rich plasma assessed as inhibition of collagen-induced platelets aggregation by aggregometry Antiplatelets aggregatory activity in human platelets rich plasma assessed as inhibition of collagen-induced platelets aggregation by aggregometry	[PMID: 19821574]
Platelet	IC₅₀	10.3 μM Compound: Aspirin	Antiplatelet activity in rabbit platelets assessed as inhibition of platelet activating factor-induced platelet aggregation Antiplatelet activity in rabbit platelets assessed as inhibition of platelet activating factor-induced platelet aggregation	[PMID: 19880317]
Platelet	IC₅₀	5.33 μM Compound: Aspirin	Antiplatelet activity in rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation Antiplatelet activity in rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation	[PMID: 19880317]
Platelet	IC₅₀	545 μM Compound: Aspirin	Antiplatelet activity in rabbit platelets assessed as inhibition of adenosin 5'-diphosphate-induced platelet aggregation Antiplatelet activity in rabbit platelets assessed as inhibition of adenosin 5'-diphosphate-induced platelet aggregation	[PMID: 19880317]
Platelet	IC₅₀	75.4 μM Compound: Aspirin	Antiplatelet aggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation by aggregometry Antiplatelet aggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation by aggregometry	[PMID: 20056545]
Platelet	IC₅₀	54 μM Compound: aspirin	Antiaggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation preincubated 10 mins before collagen challenge Antiaggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation preincubated 10 mins before collagen challenge	[PMID: 20560642]
Platelet	IC₅₀	>50 μg/mL Compound: Aspirin	Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry	[PMID: 21106454]
Platelet	IC₅₀	13.58 μg/mL Compound: Aspirin	Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry	[PMID: 21106454]
Platelet	ED₅₀	4.5 mg/kg Compound: aspirin	Inhibition of bovine collagen-induced platelet aggregation isolated from po treated Hartley guinea pig after 1 hr treatment Inhibition of bovine collagen-induced platelet aggregation isolated from po treated Hartley guinea pig after 1 hr treatment	[PMID: 214552]
Platelet	IC₅₀	54 μM Compound: 1, ASA	Antiaggregatory activity in plasma rich human platelets assessed as inhibition of collagen-induced platelet aggregation preincubated for 10 mins before collagen challenge measured 10 mins after stimulus addition Antiaggregatory activity in plasma rich human platelets assessed as inhibition of collagen-induced platelet aggregation preincubated for 10 mins before collagen challenge measured 10 mins after stimulus addition	[PMID: 21688846]
Platelet	IC₅₀	54 μM Compound: 1, ASA	Antiaggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation preincubated for 10 mins before collagen challenge measured after 10 mins by aggregometry Antiaggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation preincubated for 10 mins before collagen challenge measured after 10 mins by aggregometry	[PMID: 21906954]
Platelet	IC₅₀	6.07 μM Compound: Aspirin	Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation treated for 5 mins before ADP challenge measured for 6 mins by microplate reader Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation treated for 5 mins before ADP challenge measured for 6 mins by microplate reader	[PMID: 22137848]
Platelet	IC₅₀	>500 μM Compound: ASA	Antiplatelet activity against guinea pig platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation measured within 3 hrs by turbidimetric method Antiplatelet activity against guinea pig platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation measured within 3 hrs by turbidimetric method	[PMID: 22189137]
Platelet	IC₅₀	45 μM Compound: ASA	Antiplatelet activity against guinea pig platelet-rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation measured within 3 hrs by turbidimetric method Antiplatelet activity against guinea pig platelet-rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation measured within 3 hrs by turbidimetric method	[PMID: 22189137]
Platelet	IC₅₀	80 μM Compound: ASA	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced aggregation preincubated for 10 mins before arachidonic acid challenge by aggregometry method Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced aggregation preincubated for 10 mins before arachidonic acid challenge by aggregometry method	[PMID: 22264757]
Platelet	IC₅₀	0.15 mM Compound: ASP	Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method	[PMID: 22827516]
Platelet	IC₅₀	0.88 mM Compound: ASP	Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method	[PMID: 22827516]
Platelet	IC₅₀	58.9 μM Compound: Aspirin	Antiplatelet aggregation activity in New Zealand white rabbit platelet rich plasma assessed as inhibition of ADP-induced aggregation treated for 3 mins before ADP challenge by turbidimetric method Antiplatelet aggregation activity in New Zealand white rabbit platelet rich plasma assessed as inhibition of ADP-induced aggregation treated for 3 mins before ADP challenge by turbidimetric method	[PMID: 23394284]
Platelet	IC₅₀	>1000 μM Compound: ASA	Antiplatelet activity against collagen ADP-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method Antiplatelet activity against collagen ADP-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method	[PMID: 23425969]
Platelet	IC₅₀	183 μM Compound: ASA	Antiplatelet activity against collagen collagen-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method Antiplatelet activity against collagen collagen-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method	[PMID: 23425969]
Platelet	IC₅₀	>1000 μM Compound: ASA	Antiplatelet activity against collagen A23187-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method Antiplatelet activity against collagen A23187-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method	[PMID: 23425969]
Platelet	IC₅₀	0.14 mM Compound: ASP	Antiplatelet aggregation activity in rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation incubated for 5 mins prior to arachidonic acid-challenge measured within 5 mins by Born's turbidimetric analysis Antiplatelet aggregation activity in rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation incubated for 5 mins prior to arachidonic acid-challenge measured within 5 mins by Born's turbidimetric analysis	[PMID: 23509954]
Platelet	IC₅₀	7.76 μM Compound: Aspirin	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method	[PMID: 23639653]
Platelet	IC₅₀	7.07 μM Compound: Aspirin	Antiplatelet activity in New Zealand rabbit platelet-rich plasma assessed as inhibition of ADP-induced aggregation treated for 5 mins prior to ADP-challenge measured after 1 to 6 mins by spectrophotometric analysis Antiplatelet activity in New Zealand rabbit platelet-rich plasma assessed as inhibition of ADP-induced aggregation treated for 5 mins prior to ADP-challenge measured after 1 to 6 mins by spectrophotometric analysis	[PMID: 24565904]
Platelet	IC₅₀	5 μM Compound: Aspirin	Antiplatelet activity in human platelet-rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation treated for 5 mins prior to arachidonic acid challenge for 5 mins by turbidimetric method Antiplatelet activity in human platelet-rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation treated for 5 mins prior to arachidonic acid challenge for 5 mins by turbidimetric method	[PMID: 24859764]
Platelet	IC₅₀	>500 μM Compound: ASA	Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of ADP-induced aggregation by aggregometry Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of ADP-induced aggregation by aggregometry	[PMID: 25194932]
Platelet	IC₅₀	>500 μM Compound: ASA	Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of U46619-induced aggregation by aggregometry Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of U46619-induced aggregation by aggregometry	[PMID: 25194932]
Platelet	IC₅₀	45 μM Compound: ASA	Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of arachidonic acid-induced aggregation by aggregometry Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of arachidonic acid-induced aggregation by aggregometry	[PMID: 25194932]
Platelet	IC₅₀	37.6 μM Compound: ASA	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method relative to control Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method relative to control	[PMID: 28453995]
Platelet	IC₅₀	7.7 μM Compound: ASA	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 5 mins followed by arachidonic acid addition measured for 3 mins by aggregometric analysis Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 5 mins followed by arachidonic acid addition measured for 3 mins by aggregometric analysis	[PMID: 30108969]
Platelet	IC₅₀	1.11 μM Compound: Aspirin	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method	[PMID: 30590258]
Platelet	IC₅₀	4.5 μM Compound: Acetylsalicylic acid	Antiplatelet activity in platelet rich plasma (unknown origin) assessed as inhibition of collagen-induced platelet aggregation incubated for 5 mins by aggregometer analysis Antiplatelet activity in platelet rich plasma (unknown origin) assessed as inhibition of collagen-induced platelet aggregation incubated for 5 mins by aggregometer analysis	[PMID: 37054760]
Platelet	IC₅₀	81 μM Compound: Acetylsalicylic acid	Antiplatelet activity in platelet rich plasma (unknown origin) assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins by aggregometer analysis Antiplatelet activity in platelet rich plasma (unknown origin) assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins by aggregometer analysis	[PMID: 37054760]
Platelet	IC₅₀	18.4 μM Compound: Aspirin	Inhibition of collagen-induced platelet aggregation in rat whole blood preincubated for 3 mins followed by collagen stimulation and measured after 6 mins by aggregometer Inhibition of collagen-induced platelet aggregation in rat whole blood preincubated for 3 mins followed by collagen stimulation and measured after 6 mins by aggregometer	[PMID: 37657272]
Platelet	IC₅₀	36.2 μM Compound: 1; ASA	Antiplatelet activity in human platelets assessed as inhibition of arachidonic acid-induced platelet aggregation measured after 2 mins by turbidimetric analysis Antiplatelet activity in human platelets assessed as inhibition of arachidonic acid-induced platelet aggregation measured after 2 mins by turbidimetric analysis	[PMID: 38219659]
Platelet	IC₅₀	>200 μM Compound: Aspirin	Antiplatelet activity in human platelets assessed as inhibition of U46619-induced platelet aggregation by turbidimetric analysis Antiplatelet activity in human platelets assessed as inhibition of U46619-induced platelet aggregation by turbidimetric analysis	[PMID: 38381886]
Platelet	IC₅₀	157.1 μM Compound: Aspirin	Antiplatelet activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by turbidimetric analysis Antiplatelet activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by turbidimetric analysis	[PMID: 38381886]
Platelet	IC₅₀	30.5 μM Compound: Aspirin	Antiplatelet activity against rabbit platelet assessed as inhibition of collagen-induced platelet aggregation preincubated for 3 mins by turbidimetric method Antiplatelet activity against rabbit platelet assessed as inhibition of collagen-induced platelet aggregation preincubated for 3 mins by turbidimetric method	[PMID: 8759164]
Platelet	IC₅₀	32.7 μM Compound: Aspirin	Antiplatelet activity against rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins by turbidimetric method Antiplatelet activity against rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins by turbidimetric method	[PMID: 8759164]
Platelet	IC₅₀	20.3 μM Compound: aspirin	Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method	[PMID: 8988600]
Platelet	IC₅₀	7.7 μM Compound: ASA	Antiplatelet activity in human platelet-rich plasma assessed as inhibition of arachidonic acid-induced aggregation incubated for 5 mins prior to arachidonic acid-challenge measured for 3 mins by turbidrometric analysis Antiplatelet activity in human platelet-rich plasma assessed as inhibition of arachidonic acid-induced aggregation incubated for 5 mins prior to arachidonic acid-challenge measured for 3 mins by turbidrometric analysis	10.1007/s00044-013-0580-x
RAW264.7	IC₅₀	43.2 μM Compound: Aspirin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method	[PMID: 28561586]
SK-BR-3	IC₅₀	6.93 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human SKBR3 cells after 48 hrs by alamar blue assay Cytotoxicity against human SKBR3 cells after 48 hrs by alamar blue assay	[PMID: 22494617]
SK-BR-3	IC₅₀	7.31 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human SKBR3 cells after 24 hrs by alamar blue assay Cytotoxicity against human SKBR3 cells after 24 hrs by alamar blue assay	[PMID: 22494617]
SK-BR-3	IC₅₀	>5000000 nM Compound: ASA	Cytotoxicity against ER deficient human SKBR3 cells after 24 hrs by MTT assay Cytotoxicity against ER deficient human SKBR3 cells after 24 hrs by MTT assay	[PMID: 22916316]
SW480	IC₅₀	>5000000 nM Compound: ASA	Cytotoxicity against human SW480 cells expressing COX1 after 24 hrs by MTT assay Cytotoxicity against human SW480 cells expressing COX1 after 24 hrs by MTT assay	[PMID: 22916316]
SW480	IC₅₀	>50 μM Compound: Aspirin	Cytotoxicity against human SW480 cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human SW480 cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
U-251	EC₅₀	1341 μM Compound: 10	Antiproliferative activity against human U251MG cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human U251MG cells after 72 hrs by sulforhodamine B assay	[PMID: 30568753]
U-87MG ATCC	EC₅₀	723 μM Compound: 10	Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay	[PMID: 30568753]
UACC-903	IC₅₀	>50 μM Compound: ASA	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	>50 μM Compound: ASA	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	>50 μM Compound: ASA	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
WI-38	IC₅₀	5.01 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human WI38 cells after 48 hrs by alamar blue assay Cytotoxicity against human WI38 cells after 48 hrs by alamar blue assay	[PMID: 22494617]
WI-38	IC₅₀	6.19 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human WI38 cells after 24 hrs by alamar blue assay Cytotoxicity against human WI38 cells after 24 hrs by alamar blue assay	[PMID: 22494617]

In Vitro

Aspirin inhibits COX-1 and COX-2 in human articular chondrocytes, with IC₅₀ values of 3.57 μM and 29.3 μM, respectively^[2].
Aspirin acetylates serine-530 of COX-1, thereby blocking thromboxane A synthesis in platelets and reducing platelet aggregation^[3].
Aspirin inhibits COX-2 protein expression through interference with binding of CCAAT/enhancer binding protein beta (C/EBPbeta) to its cognate site on COX-2 promoter/enhancer^[3].
Aspirin inhibits NF-κB-dependent transcription from the lgκ enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells^[4].
Aspirin induces apoptosis by the activation of caspases, the activation of p38 MAP kinase, release of mitochondrial cytochrome c, and activation of the ceramide pathway^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Animal Model:

Male albino Charles River rats (200-250 g, 8 animals/group, fever was induced by 20 mL/kg of a 20% aqueous suspension of brewer’s yeast which was injected SC in the back below the nape of the neck)^[7]
Dosage:

5, 25, 50, 100 and 150 mg/kg
Administration:

PO, once
Result:

Produced a statistically significant decrease of 0.23°C at 15 min post-drug at the dose of 150 mg/kg. Antipyretic effect gradually increased in magnitude until a peak effect of 1.96 °C was reached at 120 min post-drug. The ED₅₀ of aspirin was found to be 10.3 mg/kg with confidence limits of 1.8-23.0 mg/kg. The antipyretic response to aspirin is dependent on the dose of the compound administered.

Animal Model:

Albino male mice ^[8]
Dosage:

500 mg/kg, single dose
Administration:

oral
Result:

Caused erosion of the surface epithelial cells.
Resulted in a decrease in the mucosal thickness.
Induced ulcer without COX-1 reaction.

Induced Disease Models

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Aspirin lithium (5-150 mg/kg, PO, once) shows significant antipyretic activity in adult yeast-fevered male rats^[7].
Aspirin can be used to induce gastrointestinal ulcer models^[8].

Induction of gastric Ulcer Model^[8]

Background

Aspirin inhibits the synthesis of endogenous prostaglandins (PGs) in animals. Aspirin can also lyse mucosal epithelial cells phospholipids, resulting in increased mucosal permeability.

Specific Modeling Methods

Mice: Albino • male • 6-week-old
Administration: 500 mg/kg • oral • single dose

Modeling Indicators

Behavior Observation: Caused erosion of the surface epithelial cell.
Resulted in a decrease in the mucosal thickness.
Induced ulcer without COX-1 reaction.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 50-78-2
Appearance Solid
Masse moléculaire 180.16
Formule C₉H₈O₄
Color White to off-white
SMILES

OC(C1=C(OC(C)=O)C=CC=C1)=O
Synonyms

Acetylsalicylic acid; ASA
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (38)

All In Vivo Efficacy StudyHistological Imaging/StainingIHCWB

Sort by:

Journal Impact Factor

Cell Host Microbe

A gut microbiota-bile acid axis promotes intestinal homeostasis upon aspirin-mediated damage. [Abstract]

2024 Feb 14;32(2):191-208.e9. PMID: 38237593

Aspirin purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2024 Feb 14;32(2):191-208.e9. [Abstract]

C57BL/6J mice were treated with aspirin [2 mg/mL (11.1 mM) in drinking water] for 2 weeks and feces collected for 16S sequencing (n=6/group). PLS-DA of 16S sequencing (n=6/group) (Asp 0d vs Asp 14d).

Aspirin purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2024 Feb 14;32(2):191-208.e9. [Abstract]

C57BL/6J mice were treated with aspirin [2 mg/mL (11.1 mM) in drinking water] for 2 weeks and feces collected for 16S sequencing (n=6/group). The three indexes of α-diversity of mice fecal microbiota (Asp 0d vs Asp 14d).

Aspirin purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2024 Feb 14;32(2):191-208.e9. [Abstract]

C57BL/6J mice were subjected to oral aspirin treatment for 2 weeks by adding aspirin into the drinking water at a concentration of 2 mg/mL (11.1mM), with or without antibiotics (neomycin). Representative images of H&E staining of intestine and injury scores for each group are shown. Random 10 positions of distal jejunum were picked and the average scores calculated for all mice (n=10 replicates/group). Scale bar: 200 μm.

Aspirin purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2024 Feb 14;32(2):191-208.e9. [Abstract]

C57BL/6J mice were subjected to oral aspirin treatment for 2 weeks by adding aspirin into the drinking water at a concentration of 2 mg/mL (11.1mM), with or without antibiotics (neomycin). Ki67 staining of distal jejunum of mice. The quantitative comparison of Ki67 staining of intestinal crypts (red dotted lines, n = 5/group) were shown.

Aspirin purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2024 Feb 14;32(2):191-208.e9. [Abstract]

Transmission Electron Microscopy (TEM) of intestinal tissues from mice subjected to oral aspirin treatment for 2 weeks by adding aspirin into the drinking water at a concentration of 2 mg/mL (11.1mM), with or without antibiotics (neomycin).
Cancer Res

A RIPK3-PGE2 Circuit Mediates Myeloid-Derived Suppressor Cell-Potentiated Colorectal Carcinogenesis. [Abstract]

2018 Oct 1;78(19):5586-5599. PMID: 30012671
Nat Commun

A mouse protozoan boosts antigen-specific mucosal IgA responses in a specific lipid metabolism- and signaling-dependent manner. [Abstract]

2024 Sep 10;15(1):7914. PMID: 39256385
Genes Dis

2026 Jun 15.
Cell Death Dis

Overexpression of homeodomain-interacting protein kinase 2 (HIPK2) attenuates sepsis-mediated liver injury by restoring autophagy. [Abstract]

2018 Aug 28;9(9):847. PMID: 30154452

Aspirin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Aug 28;9(9):847. [Abstract]

HIPK2 expression is upregulated by treatments with 5 μM Resveratrol, 30 μM Aspirin, 10 μM Vitamin E, and 15 μM Ursolic acid for another 16 h after the LPS treatment, as analysed by western blotting.
Cell Commun Signal

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer. [Abstract]

2025 Jan 15;23(1):29. PMID: 39815258
J Pharm Anal

2026 Mar 11.
Microsyst Nanoeng

High-throughput combinatorial screening of antiplatelet drugs for personalized medicine. [Abstract]

2026 Jan 1;12(1):7. PMID: 41476049
Adv Healthc Mater

Novel Drug-Testing Platform for Vascular Injury-induced Intimal Hyperplasia Using a Microphysiological System. [Abstract]

2025 Aug 11:e00602. PMID: 40787716
NPJ Sci Food

Wuliangye Baijiu but not ethanol reduces cardiovascular disease risks in a zebrafish thrombosis model. [Abstract]

2022 Dec 5;6(1):55. PMID: 36470888
Food Res Int

2026 Feb 6.
Mol Med

Aspirin attenuates the detrimental effects of TNF-α on BMMSC stemness by modulating the YAP-SMAD7 axis. [Abstract]

2024 Aug 16;30(1):126. PMID: 39152406
ACS Appl Mater Interfaces

Facile Nanocomposite Hydrogel Scaffold with Sustained Drug Release and Osteo-Immunomodulatory Effects to Enhance Bone Regeneration. [Abstract]

2025 Apr 2;17(13):19286-19303. PMID: 40116446
Cell Prolif

Aspirin reverses inflammatory suppression of chondrogenesis by stabilizing YAP. [Abstract]

2023 Apr;56(4):e13380. PMID: 36495056
Front Immunol

Aspirin Alleviates Particulate Matter Induced Asymptomatic Orchitis of Mice via Suppression of cGAS-STING Signaling. [Abstract]

2021 Dec 1:12:734546. PMID: 34925318
Neurosci Bull

A Novel Functional Method of Protector Screening for Zebrafish Lateral Line Hair Cells via the Acoustic Escape Response. [Abstract]

2025 May 6. PMID: 40329138
Ecotoxicol Environ Saf

Polystyrene microplastics induces senescence of osteocytes by activating the cyclooxygenase-2 signaling pathway. [Abstract]

2025 Jun 3:300:118466. PMID: 40466333
Int Immunopharmacol

Oxyphenbutazone suppresses non-canonical inflammasome activation and protects against LPS-induced sepsis. [Abstract]

2026 Aug 15:183:116873. PMID: 42150290
Int J Mol Sci

Rescue of Mitochondrial SIRT3 Ameliorates Ischemia-like Injury in Human Endothelial Cells. [Abstract]

2022 Aug 14;23(16):9118. PMID: 36012382
Front Pharmacol

Hsp47 Inhibitor Col003 Attenuates Collagen-Induced Platelet Activation and Cerebral Ischemic-Reperfusion Injury in Rats. [Abstract]

2022 Jan 10;12:792263. PMID: 35082674
Front Cell Dev Biol

Chlorpromazine affects autophagy in association with altered Rag GTPase-mTORC1-TFEB signaling. [Abstract]

2023 Sep 8:11:1266198. PMID: 37745295
ACS Omega

Purification and Characterization of Novel Collagen Peptides against Platelet Aggregation and Thrombosis from Salmo salar. [Abstract]

2020 Aug 4;5(32):19995-20003. PMID: 32832753
Spectrochim Acta A Mol Biomol Spectrosc

Harmonizing drug analysis and sustainability: Spectroscopic quantification of antiplatelet-anticoagulant regimens. [Abstract]

2026 Jan 15:345:126769. PMID: 40779897
J Cell Mol Med

Aspirin Attenuates Liver Fibrosis via Autophagy Induction. [Abstract]

2025 Jul;29(13):e70696. PMID: 40611443
Brain Res Bull

Cycloastragenol protected hippocampal CA1 neurons by regulating redox homeostasis and alleviated cognitive impairment following cerebral ischemia-reperfusion. [Abstract]

2025 Dec 15:234:111689. PMID: 41407128
Mol Nutr Food Res

Aqueous Extract of Wolfberry Alleviates Aging-Related Skeletal Muscle Dysfunction by Modulating PRRs Signaling Pathways and Enhancing DNA Repair. [Abstract]

2024 Aug 1:e2400307. PMID: 39091066
Clin Chim Acta

Simultaneous quantification of acetylsalicylic acid, clopidogrel, ticagrelor and their major metabolites in human plasma by liquid chromatography-tandem mass spectrometry. [Abstract]

2025 Dec 31:120816. PMID: 41482259
Funct Integr Genomics

Integration of transcriptome and mendelian randomization elucidates the protective role of aspirin in pulmonary tuberculosis development. [Abstract]

2026 Jun 23;26(1):155. PMID: 42332333
Neurotoxicology

Aspirin ameliorates the cognition impairment in mice following benzo[a]pyrene treatment via down-regulating BDNF IV methylation. [Abstract]

2022 Mar:89:20-30. PMID: 34979192
Food Chem Toxicol

Aspirin ameliorates the neurotoxicity of benzo[a]pyrene in mice and HT22 cells: Possible role of miRNA-mRNA network. [Abstract]

2023 Aug:178:113919. PMID: 37364758
J Appl Toxicol

Differential impacts of nonsteroidal anti-inflammatory drugs on lifespan and healthspan in aged Caenorhabditis elegans. [Abstract]

2024 Oct;44(10):1528-1539. PMID: 38840409
PLoS One

Preventive effect and mechanism of Tibetan tea extract on thrombosis in arachidonic acid-induced zebrafish determined via RNA-seq transcriptome profiles. [Abstract]

2023 May 19;18(5):e0285216. PMID: 37205684
Biomed Rep

Toxicity evaluation and anti-ischemic stroke activity of selected natural extracts in zebrafish. [Abstract]

2026 Jun 24;25(2):99. PMID: 42388451
STAR Protoc

Protocol for targeting the magnocellular neuroendocrine cell ensemble via retrograde tracing from the posterior pituitary. [Abstract]

2021 Aug 27;2(3):100787. PMID: 34485946
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
bioRxiv

2025 January 21.
Oxid Med Cell Longev

Cepharanthine Attenuates Early Brain Injury after Subarachnoid Hemorrhage in Mice via Inhibiting 15-Lipoxygenase-1-Mediated Microglia and Endothelial Cell Ferroptosis. [Abstract]

2022 Feb 9;2022:4295208. PMID: 35186185
Eur Rev Med Pharmacol Sci

Autophagy assuages myocardial infarction through Nrf2 signaling activation-mediated reactive oxygen species clear. [Abstract]

2020 Jul;24(13):7381-7390. PMID: 32706077

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (555.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 3.12 mg/mL (17.32 mM; ultrasonic and warming and heat to 37°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.5506 mL

27.7531 mL

55.5062 mL

5 mM

1.1101 mL

5.5506 mL

11.1012 mL

10 mM

0.5551 mL

2.7753 mL

5.5506 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (13.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (13.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (13.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Saline

Solubility: 5 mg/mL (27.75 mM); Clear solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 5 mg/mL (27.75 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (288 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and induciblecyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7. [Content Brief]

[2]. Blanco FJ, et al. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [Content Brief]

[3]. Wu KK, et al. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [Content Brief]

[4]. Kopp E, et al. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994 Aug 12;265(5174):956-9. [Content Brief]

[5]. Burch JW, et al. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978 Feb;61(2):314-9. [Content Brief]

[6]. Elwood PC, et al. Aspirin, salicylates, and cancer. Lancet. 2009 Apr 11;373(9671):1301-9. [Content Brief]

[7]. Loux JJ, DePalma PD, Yankell SL. Antipyretic testing of aspirin in rats. Toxicol Appl Pharmacol. 1972 Aug;22(4):672-5. [Content Brief]

[8]. Yomna I Mahmoud, et al. Spirulina ameliorates aspirin-induced gastric ulcer in albino mice by alleviating oxidative stress and inflammation. Biomed Pharmacother. 2019. [Content Brief]

[9]. Zhongzhi Wang, et al. Protective Effects of Ginger against Aspirin-Induced Gastric Ulcers in Rats. Yonago Acta Med. 2011, 54, 1.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	5.5506 mL	27.7531 mL	55.5062 mL	138.7655 mL
	5 mM	1.1101 mL	5.5506 mL	11.1012 mL	27.7531 mL
	10 mM	0.5551 mL	2.7753 mL	5.5506 mL	13.8766 mL
	15 mM	0.3700 mL	1.8502 mL	3.7004 mL	9.2510 mL
DMSO	20 mM	0.2775 mL	1.3877 mL	2.7753 mL	6.9383 mL
	25 mM	0.2220 mL	1.1101 mL	2.2202 mL	5.5506 mL
	30 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6255 mL
	40 mM	0.1388 mL	0.6938 mL	1.3877 mL	3.4691 mL
	50 mM	0.1110 mL	0.5551 mL	1.1101 mL	2.7753 mL
	60 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	80 mM	0.0694 mL	0.3469 mL	0.6938 mL	1.7346 mL
	100 mM	0.0555 mL	0.2775 mL	0.5551 mL	1.3877 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Aspirin

38 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Aspirin

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Animal Disease Model Inducer Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Pediatric Drug Library

Antidepressant Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Osteogenesis Compound Library

Anti-Aging Natural Product Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Protease Inhibitor Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Nephrotoxicity Compound Library

Environmental Pollutant Compound Library

RNA Binding Bioactive Compound Library